[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"melatonin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:melatonin":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,72,101,131,164,191,218],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100054105","phase-4-effects-of-melatonin-on-sleep-architecture-of-critically-ill-patients-in-the-icu-100054105",false,"NCT07691996","Effects of Melatonin on Sleep Architecture of Critically Ill Patients in the ICU","Inclusion Criteria:\n\n* 18 years or older, admitted to the ICU\n* Expected length of stay of at least 48 hours\n* Not mechanically ventilated\n* Able to take oral medications.\n* Hemodynamically stable as determined by the treating ICU physician\n* Able to provide informed consent or have consent provided by a legally -authorized representative.\n\nExclusion Criteria:\n\n* Mechanically ventilated\n* Currently using melatonin prior to ICU admission,\n* Have neurological conditions that may significantly alter sleep architecture, such as traumatic brain injury, stroke, or severe dementia.\n* Pregnant or lactating individuals\n* Those individuals with a comfort measures-only status","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","This is a pilot study to examine the effects of melatonin on the sleep patterns of critically ill patients. Patients will have their sleep patterns measured with a device attached to their head with a headband then be given a dose of melatonin. Their participation in the study will last two days.",[25,26,27,28,29],"Critical Illness","ICU","ICU Hospitalization","Melatonin","Sleep","NOT_YET_RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":19},"2026-09-01",{"date":38,"type":19},"2028-01",{"name":40,"class":41},"Rutgers, The State University of New Jersey","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100619426","oral-melatonin-versus-oral-pregabalin-on-postoperative-pain-and-anxiety-following-spine-surgery-100619426","NCT07344467","Oral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery","Effect of Oral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 21-60 years old.\n* Both sexes.\n* Patients of American Society of Anesthesiologists (ASA) physical status I \\& II.\n* Undergoing elective spine surgery.\n\nExclusion Criteria:\n\n* Patient refusal.\n* History of allergic reactions to melatonin or pregabalin.\n* Patients with cardiovascular disease (ischemic heart disease, Heart Failure, Arrythmia, Heart Block).\n* Patients with kidney disease with (plasma creatinine level \\> 1.5mg\u002Fdl).\n* Patients with liver disease with (aspartate transaminase, alanine transaminase, and bilirubin levels more than twice the upper limit of normal).\n* Psychological and cognitive disorders; dementia; major depression.\n* Circadian rhythm disorders such as chronic fatigue syndrome and drowsiness.","21 Years","60 Years",{"count":52,"type":19},105,[54],"NA","This study aims to compare the efficacy of using Melatonin versus Pregabalin on postoperative pain and anxiety after spine surgeries.",[57,28,58,59,60,61],"Oral","Pregabalin","Postoperative Pain","Anxiety","Spine Surgery","RECRUITING","2026-01-17",{"date":65,"type":34},"2026-01-21",{"date":63,"type":34},{"date":68,"type":19},"2027-06-01",{"name":70,"class":41},"Tanta University",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":16,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":20,"phases":83,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":71},"100619810","cardioprotective-effect-of-melatonin-versus-vitamin-d-in-breast-cancer-patients-receiving-doxorubicin-100619810","NCT07349459","Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin","Clinical Study Evaluating Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin","Inclusion Criteria:\n\n* Age from 18 to 65 years old.\n* Gender: female.\n* Positive breast cancer women who are scheduled to receive Doxorubicin.\n* Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.\n* Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.\n* Normal renal and liver function tests.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Women with HER-2 positive of breast cancer.\n* Formerly treated with Doxorubicin.\n* Patients with a known hypersensitivity to any of the used drugs.\n* On other concomitant vitamins or food supplements.\n* Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.\n* Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction \\\u003C 50%.","FEMALE","65 Years",{"count":82,"type":19},90,[54],"This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.",[28,86,87,88],"Breast Cancer Patients Diagnosed","Vitamin D Concentration","Doxorubicin",[90,88,91,28,92],"Vitamin D","Cardioprotective Effect","Breast Cancer Patients","2026-01-09",{"date":95,"type":34},"2026-01-16",{"date":97,"type":19},"2026-04-30",{"date":99,"type":19},"2026-08-30",{"name":70,"class":41},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":20,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":71},"100447554","light-in-frail-elderly---the-effect-of-a-dynamic-light-for-sleep-and-circadian-rhythm-100447554","NCT05107947","Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm","LIFE","Inclusion Criteria:\n\n* Over the age of 65 years\n* Admitted to one of the included study rooms\n\nExclusion Criteria:\n\n* Overdose addictive substance\n* Acute neurological disease\n* Melatonin treatment\n* Probable survival \\\u003C5 days\n* Severe visual impairment that makes reading impossible\n* Age \\\u003C65 years\n* Inability to understand Swedish in speech and writing\n* Inability to consent to participate in the study\n* The patient is on any of the following medicines:\n\n  * Medications for Parkinson's disease\n  * Neuroleptics (including lithium)\n  * Dementia",{"count":109,"type":19},300,[54],"The aim of this project is to evaluate the effect of a dynamic light in order to improve the circadian rhythm, provide a better sleep and well-being, and in the long run an improved recovery. The primary question is whether dynamic artificial light with circadian stimulus can affect the circadian rhythm. The secondary question is whether this also provides better sleep and well-being.\n\nThe group that is particularly interesting to study is a geriatric population that is more sensitive to circadian rhythm disorders, sleep disorders and confusion in connection with hospitalization and that can be of particular benefit from this intervention.",[113,114,115,116,117,118,28,29,119,120,121,122],"Aged","Circadian Rhythm","Cognition","Fatigue","Humans","Light","Biocentric","Frailty","Karolinska Sleepiness Score","Inflammation",{"date":124,"type":34},"2026-01-12",{"date":126,"type":34},"2022-10-31",{"date":128,"type":19},"2028-09",{"name":130,"class":41},"Region Skane",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":20,"phases":142,"briefSummary":143,"conditions":144,"keywords":149,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100568905","light-in-healthcare-environment-ljus-i-sjukhusmilj-100568905","NCT06687304","Light in Healthcare Environment (Ljus i sjukhusmiljö)","Benefits of Light in the Radiographic Environment","LIS","Inclusion Criteria:\n\nRadiographer\n\nExclusion Criteria:\n\n\\-",true,{"count":141,"type":19},18,[54],"The goal of this clinical trial is to learn if light can enhance the feeling of well-being and sleep quality in Radiographers. It will also find out if there is an optimal recipe for light. The main questions it aims to answer are:\n\n* Will alertness, energy levels, and sleep quality increase in radiographers when the lighting is differed?\n* What light recipe is the most beneficial for the personnel? Researchers will compare no enhanced light environment to different enhanced light environment to see if the enhanced light is beneficial for radiographers.\n\nParticipants will:\n\n* Will work in an enhanced light environment or a non-enhanced light environment\n* Answer surveys\n* Take saliva sample",[145,146,28,147,148],"Sleep Quality","Well-being","Cortisol","Energy Levels",[118,150,151,152,153],"Radiography","Light environment","Circadian rhythm","Personnel at radiology departments","2025-11-24",{"date":156,"type":34},"2025-12-02",{"date":158,"type":34},"2024-11-15",{"date":160,"type":19},"2027-03-31",{"name":162,"class":41},"Lund University",3,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":20,"phases":173,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100578319","phase-2-evaluating-efficacy-and-safety-of-oral-melatonin-in-acute-central-serous-chorioretinopathy-100578319","NCT06809751","Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy","Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy (CSCR): a Double-blind Randomized Clinical Trial","Inclusion Criteria:\n\n1. Patients whose diagnosis of central serous chorioretinopathy is confirmed based on clinical and imaging criteria within the past 6 weeks\n2. Patients with minimum age of 18 years old\n3. Consent to participate in the study\n\nExclusion Criteria:\n\n1. A history of vitrectomy\n2. A history of laser surgery in the eye being studied in the past 3 months\n3. A history of anti-VEGF injection in the eye being studied in the past 3 months\n4. History of patient suspicious for choroidal neovascularization (CNV)\n5. Pregnant or nursing patients\n6. Patients with significantly compromised visual acuity in the eye being studied due to concomitant ocular condition\n7. Patients participating in any other investigational drug study\n8. Inability to obtain OCT photographs",{"count":172,"type":19},48,[174,175],"PHASE2","PHASE3","The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are:\n\n1. How does melatonin affect central macula thickness in CSCR?\n2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR.\n\nParticipants will:\n\n1. Take melatonin or placebo twice a day for one month\n2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests\n3. Keep a diary of their symptoms",[178,28,179,180,181],"Central Serous Chorioretinopathy","Ocular Diseases","Visual Acuity","Macula Abnormality","2025-01-30",{"date":184,"type":34},"2025-02-05",{"date":186,"type":19},"2025-02-01",{"date":188,"type":19},"2025-06-01",{"name":190,"class":41},"Mohsen Pourazizi",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":20,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100574249","effects-of-3-month-melatonin-treatment-on-regional-cerebellar-structure-and-blood-biomarkers-in-alzheimers-disease-spectrum-100574249","NCT06756828","Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer's Disease Spectrum","Study on Regional Structural Changes in the Cerebellum Associated with Blood Biomarkers, Cognitive Decline, and Physical Performance in Alzheimer's Spectrum Patients Following a 3-Month Melatonin Treatment Using Digital Health Technology","Inclusion Criteria:\n\n* Male and female participants aged 60 to 90 years\n* Individuals presenting with cognitive impairment as their chief complaint at the Department of Psychiatry, St. Vincent's Hospital\n* Those capable of undergoing imaging studies, including Brain MRI and Amyloid PET CT\n* Individuals able to complete cognitive function tests, such as the Alzheimer's Disease Consortium test battery, K-MMSE, CDR, and GDS\n* Participants who can perform tests at the hospital's Smart Center, including the Short Physical Performance Battery and body composition analysis using direct segmental multi-frequency bioelectrical impedance analysis for sarcopenia\n* Individuals on acetylcholinesterase inhibitors (ACEi) or NMDA receptor antagonists who have maintained the same dosage and regimen for more than 3 months from the screening date.\n* Patients who are taking medications for cognitive function treatment other than acetylcholinesterase inhibitors and NMDA receptor antagonists (e.g., pregabalin, gabapentin, choline alfoscerate), as well as medications for chronic diseases such as antidepressants, antihypertensives, diabetes, hyperlipidemia, thyroid disorders, etc., must have maintained the same dosage and regimen for more than 1 month from the screening date.\n* Individuals with sufficient language proficiency to read and understand the informed consent document and respond to survey questionnaires\n\nExclusion Criteria:\n\n* Individuals with progressive mental or neurological disorders (including those with a history of psychotic disorders such as major depressive disorder, bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, or unspecified psychosis; patients currently experiencing major depressive disorder with psychotic symptoms; organic mental disorders; epilepsy or seizure disorders; patients currently suffering from eating disorders or obsessive-compulsive disorder).\n* Individuals with unstable or severe medical conditions.\n* Patients with severe snoring, REM sleep behavior disorder, or narcolepsy.\n* Illiterate individuals.\n* Individuals who, in the opinion of the investigator, are deemed unable to comply with the requirements of the study.\n* Patients currently taking sleeping pills within 2 weeks of the screening point.","90 Years",{"count":200,"type":19},40,[54],"The goal of this clinical trial is to explore and verify the preventive effects of melatonin on the progression of Alzheimer's disease. The study aims to analyze the changes in blood biomarkers (phosphorylated tau, glial fibrillary acidic protein, neurofilament chain), various sleep-related subjective report questionnaire scores, physical performance, cognitive function scores and cerebellar volume change after three months of melatonin administration in patients with Alzheimer's-type mild cognitive impairment (MCI) accompanied by insomnia. The main questions it aims to answer are:\n\n1. Does melatonin administration alter the levels of blood biomarkers associated with Alzheimer's disease?\n2. What changes occur in sleep-related subjective report questionnaire scores and cognitive function scores following melatonin administration?\n3. Does melatonin administration effect on physical performance?\n4. Is there any relations between cognitive decline, phsycal performance and cerebellar volume change? We will compare the data collected before and after melatonin administration to determine its preventive effects on Alzheimer's disease progression.\n\nParticipants Will:\n\n1. Take melatonin every day for 3 months and Complete sleep-related subjective report questionnaires, neuropsychological assessments and physical performance test\n2. Visit the clinic at the initial visit and after 3 months for checkups and tests.\n3. Complete sleep-related subjective report questionnaires and neuropsychological assessments and physical performance test\n4. Provide blood samples for biomarker analysis.",[204,205,28,206,207,208],"Elderly","Alzheimer Disease","Cognitive Decline","Biomarker with Neurodegeneration Patients","Cerebellum","2024-12-23",{"date":211,"type":34},"2025-01-03",{"date":213,"type":19},"2025-01-15",{"date":215,"type":19},"2026-12-30",{"name":217,"class":41},"Saint Vincent's Hospital, Korea",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":15,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":71},"100554709","idiopathic-scoliosis-new-onset-and-melatonin-phase-delay-in-children-100554709","NCT06502613","Idiopathic Scoliosis New Onset and Melatonin Phase Delay in Children","Melatonin Phase Delay May Increase Risk of Children and Adolescent Idiopathic Scoliosis.","Inclusion Criteria:\n\n* Collect saliva according to standards and complete melatonin testing\n\n  * Complete scoliometer or X-ray assess scoliosis\n  * Skeletally immature (Risser Sign 0-3)\n  * Age between 6 and 15\n  * Patients can understand and complete the MEQ-5, PSQ, and PSQI Questionnaire at baseline and follow-up visits\n  * Informed Consent Form signed by subject or the guardian\n\nExclusion Criteria:\n\n\\-","6 Years","15 Years",{"count":228,"type":19},956,"OBSERVATIONAL","This study aimed to investigate the prevalence and clinical significance of melatonin phase delay in children with new onset and progressive idiopathic scoliosis (IS).",[232,114,28],"Scoliosis Idiopathic",[28,234],"Scoliosis","2024-07-14",{"date":237,"type":34},"2024-07-16",{"date":239,"type":19},"2024-08-01",{"date":241,"type":19},"2027-07-15",{"name":243,"class":41},"Second Affiliated Hospital of Wenzhou Medical University"]